EX-99.1 2 a08-20260_1ex99d1.htm EX-99.1

Exhibit 99.1

 

For Immediate Release

For Further Information Contact:

Andrew Fisher at (202) 483-7000

Email: Afisher@unither.com

 

UNITED THERAPEUTICS REPORTS

SECOND QUARTER 2008 FINANCIAL RESULTS

 

·                                  Revenues of $68.6 Million, Increase of 32% Over Second Quarter 2007

 

·                                  EPS of $0.63 per Basic Share, Increase of 125% Over Second Quarter 2007

 

·                                  Earnings Before Non-Cash Charges of $1.36 per Basic Share, Increase of 56% Over Second Quarter 2007

 

Silver Spring, MD, July 31, 2008:  United Therapeutics Corporation (NASDAQ: UTHR) today announced its results of operations for the quarter ended June 30, 2008.

 

Total revenues for the second quarter of 2008 were $68.6 million, up 32.3% from $51.8 million for the second quarter of 2007.  Net income for the second quarter of 2008 was $14.3 million, or $0.63 per basic share, compared to $5.8 million, or $0.28 per basic share, for the second quarter of 2007.  Gross margins from sales were $60.6 million in the second quarter of 2008, compared to $45.8 million in the second quarter of 2007.  The increases in revenues and gross margins corresponded to the growth in sales of our lead product, Remodulin.  Earnings before non-cash charges, defined as net income before non-cash income taxes, depreciation, amortization, impairment charges and share-based compensation (stock option and share tracking award expense), were $30.7 million for the second quarter of 2008, up 70.3% from $18.0 million for the second quarter of 2007.

 

“It is gratifying that we are on track to grow our annual revenues in excess of 30% for the sixth consecutive year,” said Martine Rothblatt, Ph.D., United Therapeutics’ Chairman and Chief Executive Officer.  “I am also pleased that, after twelve years of operations, our accumulated deficit has been eliminated and we are now able to report accumulated earnings. These financial accomplishments reflect the decisions of hundreds of doctors and patients to use Remodulin and make it the leading form of prostacyclin therapy in the United States.”

 


 

Research and Development Expenses

 

The table below summarizes research and development expenses by major project and non-project components (dollars in thousands):

 

 

 

Three Months Ended 
June 30,

 

Percentage

 

 

 

2008

 

2007

 

Change

 

Project and non-project:

 

 

 

 

 

 

 

Cardiovascular

 

$

11,890

 

$

9,269

 

28.3

%

Cancer

 

177

 

4,061

 

(95.6

)%

Infectious disease

 

220

 

200

 

10.0

%

Share-based compensation

 

3,313

 

2,981

 

11.1

%

Other

 

3,541

 

1,459

 

142.7

%

Total research and development expense

 

$

19,141

 

$

17,970

 

6.5

%

 

The increase in cardiovascular expenses was primarily due to increased expenses related to our inhaled and oral treprostinil programs.

 

Selling, General and Administrative Expenses

 

The table below summarizes selling, general and administrative expenses by major category (dollars in thousands):

 

 

 

Three Months Ended
June 30,

 

Percentage

 

 

 

2008

 

2007

 

Change

 

Category:

 

 

 

 

 

 

 

General and administrative

 

$

9,444

 

$

9,066

 

4.2

%

Sales and marketing

 

9,316

 

5,708

 

63.2

%

Share-based compensation

 

4,333

 

5,700

 

(24.0

)%

Total selling, general and administrative expenses

 

$

23,093

 

$

20,474

 

12.8

%

 

The increase in sales and marketing related expenses reflects increases in salary and related expenses and professional fees incurred in connection with new marketing campaigns and initiatives.

 


 

Earnings Before Non-Cash Charges

 

The following table provides a reconciliation of net income to earnings before non-cash charges for the three-month periods ending June 30, 2008 and 2007, respectively (in thousands, except per share data):

 

 

 

Three Months Ended
June 30,

 

 

 

2008

 

2007

 

 

 

 

 

 

 

Net income, as reported

 

$

14,331

 

$

5,806

 

Add back:

 

 

 

 

 

Income tax expense

 

7,553

 

2,724

 

Depreciation and amortization

 

1,028

 

796

 

Impairment charges

 

152

 

—

 

Share-based compensation

 

7,661

 

8,714

 

Earnings before non-cash charges

 

$

30,725

 

$

18,040

 

Earnings before non-cash charges per share (1):

 

 

 

 

 

Basic

 

$

1.36

 

$

0.87

 

Diluted

 

$

1.26

 

$

0.82

 

 

(1)   Calculated by dividing earnings before non-cash charges by the weighted average shares outstanding, as reported below.

 

Conference Call

 

United Therapeutics will host a half-hour teleconference on Thursday, July 31, 2008, at 9:00 a.m. Eastern Time.  The teleconference is accessible by dialing 1-800-603-1777, with international callers dialing 1-706-679-8129.  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291, and using conference code: 56186490.

 

This teleconference is also being webcast and can be accessed via United Therapeutics’ website at http://ir.unither.com/events.cfm.

 

About United Therapeutics

 

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

 


 

Non-GAAP Financial Information

 

This press release contains a financial measure that does not comply with U.S. generally accepted accounting principals (GAAP). This measure supplements our financial results prepared in accordance with GAAP as reported below.

 

We use earnings before non-cash charges, a financial non-GAAP measure, internally for operating, budgeting and financial planning purposes and as a metric to determine the efficiency of our operations.  We believe our investors’ understanding of our performance is enhanced by disclosing this measure.  The presentation of this non-GAAP financial measure is not to be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.

 

Forward-looking Statements

 

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, among others, our expectations and intentions related to annual revenue growth and our ability to maintain our accumulated earnings.  These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.  Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.  We are providing this information as of July 31, 2008, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

 

Remodulin is a registered trademark of United Therapeutics Corporation. [uthr-g]

 

*              *              *

 


 

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)

 

 

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

 

 

(Unaudited)

 

(Unaudited)

 

Revenues:

 

 

 

 

 

 

 

 

 

Net product sales

 

$

65,497

 

$

49,381

 

$

124,650

 

$

87,788

 

Service sales

 

2,393

 

1,783

 

4,620

 

3,545

 

Distributor fees

 

666

 

667

 

1,333

 

667

 

Total revenues

 

68,556

 

51,831

 

130,603

 

92,000

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

19,141

 

17,970

 

40,217

 

46,084

 

Selling, general and administrative

 

23,093

 

20,474

 

42,424

 

35,638

 

Cost of product sales

 

6,564

 

4,791

 

12,739

 

8,606

 

Cost of service sales

 

768

 

551

 

1,479

 

1,132

 

Total operating expenses

 

49,566

 

43,786

 

96,859

 

91,460

 

Income from operations

 

18,990

 

8,045

 

33,744

 

540

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

Interest income

 

2,804

 

1,938

 

6,412

 

5,983

 

Interest expense

 

—

 

(713

)

—

 

(1,424

)

Equity loss in affiliate

 

(43

)

(79

)

(156

)

(193

)

Other, net

 

817

 

(279

)

525

 

(220

)

Total other income, net

 

3,578

 

867

 

6,781

 

4,146

 

Income before income tax

 

22,568

 

8,912

 

40,525

 

4,686

 

Income tax expense

 

(8,237

)

(3,106

)

(14,792

)

(1,661

)

 

 

 

 

 

 

 

 

 

 

Net income

 

$

14,331

 

$

5,806

 

$

25,733

 

$

3,025

 

 

 

 

 

 

 

 

 

 

 

Net income per common share:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.63

 

$

0.28

 

$

1.15

 

$

0.14

 

Diluted

 

$

0.59

 

$

0.26

 

$

1.07

 

$

0.14

 

Weighted average number of common shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

22,600

 

20,837

 

22,467

 

21,069

 

Diluted

 

24,328

 

22,020

 

24,120

 

22,219

 

 

CONSOLIDATED BALANCE SHEET DATA

As of June 30, 2008

(Unaudited, in thousands)

 

Cash, cash equivalents and marketable investments
(excluding restricted amounts of $45,037)

 

$

342,741

 

Total assets

 

$

679,818

 

Total liabilities & common stock subject to repurchase

 

$

316,411

 

Total stockholders’ equity

 

$

363,407